An experimental treatment from Shionogi & Co Ltd has shown rapid clearance of the virus that causes COVID-19, according to new data, the Japanese drug maker said on Sunday.
The pill, S-217622, “demonstrated rapid clearance of the infectious SARS-CoV-2 virus”, Shionogi said in a statement, citing Phase-2b results from the Phase II/III clinical trial of the drug.
The company has global aspirations for the antiviral pill, which is now being evaluated by Japanese regulators.
Related – How does Merck’s COVID-19 pill compare to Pfizer’s?
The findings released on Sunday also showed “there was no significant difference in total score of 12 COVID-19 symptoms between treatment arms” although the drug showed improvement in a composite score of five “respiratory and feverish” symptoms, Shionogi said.
The drugmaker said in March it would launch a global Phase III trial worldwide for the drug with U.S. government support, and Chief Executive Isao Teshirogi has said production could reach 10 million doses a year.
Shionogi’s shares have been on a rollercoaster on speculation about success of the treatment. The stock climbed on Friday after a report the U.S. government is in talks to acquire supplies of the drug.
On April 13 the stock sank by as much as 16% on reports the drug could pose risks to pregnancies, based on preclinical data.
from Health News - Latest breaking Health News - ARY NEWS https://ift.tt/7VsvLXn
0 Comments